An in vitro study evidenced that SMAD-3 is crucially involved in the 5-FU-resistant pathway in CRC by modulating TGF-β downstream genes with pro-proliferative, pro-metastatic, and anti-apoptotic effects [60]. The gene discussed is SMAD3; the disease is colorectal carcinoma.